Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,867 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions: Metformin 500 Mg Oral Tablet, up to 4 tablets a day, Placebo oral tablet identical to metformin, up to 4 tablets a day; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 30 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Obstructive Sleep Apnea
Interventions: Trillium Full Face Mask, AirFit F20; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Lehigh Acres, Florida

Conditions: Skin Laxity
Interventions: Ulthera® System Treatment, Heavy Water; Device · Other
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Acute Myelogenous Leukemia
Interventions: SAR103168; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Atlanta, Georgia • New York, New York • Houston, Texas

Conditions: Adrenoleukodystrophy, Restless Legs Syndrome
Interventions: Pramipexole, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Stroke
Interventions: LSVT®BIG Intervention, Waitlist Control; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Metastatic Colorectal Cancer
Interventions: Bevacizumab, Oxaliplatin, Leucovorin, Fluorouracil, Cetuximab; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 82
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 74 more

Conditions: Atropine Bioequivalence
Interventions: Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL); Drug
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Tourette Syndrome, Chronic Tic Disorder
Interventions: Behavior Therapy for Tics (CBIT); Behavioral
Lead sponsor: University of Wisconsin, Milwaukee; Other
Eligibility: 8 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Cognitive Impairment
Interventions: Speed of Processing Training, Transfer Package from CI Therapy; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Hyperbaric Oxygen; Device
Lead sponsor: Legacy Health System; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF), Primary Myelofibrosis (PMF)
Interventions: Bomedemstat; Drug
Lead sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acute Lung Injury
Interventions: Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis; Drug · Other · Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Clackamas, Oregon • Portland, Oregon

Conditions: Psychosis, Schizoaffective Disorder, Schizophrenia
Interventions: OnTrack>TheGame (OTG), Recovery Videos (RV); Behavioral
Lead sponsor: Center for Social Innovation, Massachusetts; Other
Eligibility: 16 Years to 30 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Gynecologic Neoplasm, Brachytherapy, Therapeutic Touch, Endometrial Cancer, Cervical Cancer, Vaginal Cancer, Vulvar Cancer
Interventions: Reiki therapy; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Kidney Transplantation in Highly Sensitized Patients
Interventions: Imlifidase; Drug
Lead sponsor: Hansa Biopharma AB; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Obstructive Sleep Apnea
Interventions: AD036 Dose 1, AD036 Dose 2, AD036 Dose 3, Placebo; Drug
Lead sponsor: Apnimed; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 12
States / cities: Glendale, Arizona • Little Rock, Arkansas • Redwood City, California + 9 more

Conditions: Melanoma
Interventions: autologous tumor cells plus GM-CSF-in Adjuvant; Biological
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Andersen-Tawil Syndrome
Interventions: Potassium, Acetazolamide; Dietary Supplement · Drug
Lead sponsor: University of Rochester; Other
Eligibility: 10 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Batefenterol, Umeclidinium/ Vilanterol, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Hialeah, Florida • Baltimore, Maryland • St Louis, Missouri + 6 more

Conditions: Glabellar Lines, Lateral Canthal Lines
Interventions: MT10109L, Placebo; Drug
Lead sponsor: Medy-Tox; Industry
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 9
States / cities: Glendale, Arizona • Newport Beach, California • Coral Gables, Florida + 6 more

Conditions: Mild Cognitive Impairment, Primary Progressive Aphasia, Dementia
Interventions: Computerized Cognitive Training, Active tDCS (tDCS) on DLPFC; Other · Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Insomnia
Interventions: SHUTi, modified SHUTi (i.e., SHUTi-BWHS), Patient education; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 45 Years to 85 Years · Female only
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rare Diseases
Interventions: FAmily CEntered (FACE) pACP Intervention; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 1 Year to 99 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

Metformin Treatment in Progressive Multiple Sclerosis

A Phase II Pilot Study of the Trillium Full Face Mask

Feasibility Study: Heavy Water Tissue Labeling Protocol

Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes

Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

Feasibility of the Lee Silverman Voice Treatment®-BIG Intervention in Stroke

Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer

Sublingual Atropine Bioequivalence by Route of Administration (SABER)

VoIP Delivered Behavior Therapy for Tourette Syndrome

Improving Thinking in Everyday Life: Pilot Study A

Effects of HBO on Glucose in Patients With DM

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Hemodynamics and Extravascular Lung Water in Acute Lung Injury

OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis

Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies

A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation

Trial of AD036 in Obstructive Sleep Apnea

Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma

Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome

Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)

Home-based tDCS in Frontotemporal Dementia or Alzheimer's Disease

Reducing Health Disparities for Black Women in the Treatment of Insomnia

FACE for Children With Rare Diseases